Researchers have introduced a highly promising new approach for the development of drugs to treat pneumococci, which cause pneumonia and meningitis. They copied the choline architecture of the pneumococcal cell wall. They were then able to trap the choline-binding proteins that have a critical effect on the infectiousness of pneumococcal bacteria.